Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I study with repeated doses of the Multiple Ascending Dose of RMC-035

Trial Profile

A Phase I study with repeated doses of the Multiple Ascending Dose of RMC-035

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 14 Nov 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RMC 035 (Primary)
  • Indications Acute kidney injury; Preeclampsia; Radiation injuries
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Nov 2018 New trial record
    • 09 Nov 2018 According to an A1M Pharma AB media release, the Swedish Medicines Agency has given permission to initiate the Phase I clinical trial of ROSgard. Single Ascending Dose part is expected to start in the first quarter of 2019 and Multiple Ascending Dose part in the second half of 2019.
    • 01 Nov 2018 According to an A1M Pharma AB media release, this study is expected to be initiated during the second half of 2019, and results are expected in the first quarter of 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top